

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 May 2025 (08.05.2025)



(10) International Publication Number
WO 2025/093572 A1

(51) International Patent Classification:

A61K 9/107 (2006.01) A61K 47/12 (2006.01)
A61K 9/14 (2006.01) A61K 47/14 (2017.01)
A61K 9/16 (2006.01)

(21) International Application Number:

PCT/EP2024/080621

(22) International Filing Date:

29 October 2024 (29.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/594,010 29 October 2023 (29.10.2023) US

(71) Applicant: **TRX BIOSCIENCES LIMITED** [GB/GB];
The Walbrook Building, 25 Walbrook, London EC4N 8AF
(GB).

(72) Inventors: **GOODING, Daniel**; c/o TRx Biosciences Limited,
The Walbrook Building, 25 Walbrook, London EC4N 8AF (GB). **BREW, John**; c/o TRx Biosciences Limited,
The Walbrook Building, 25 Walbrook, London EC4N 8AF (GB). **BANNISTER, Robin M.**; c/o TRx Biosciences Limited,
The Walbrook Building, 25 Walbrook, London EC4N 8AF (GB).

(74) Agent: **SCHLICH**; 9 St. Catherine's Road, Littlehampton,
Sussex BN17 5HS (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: SOLID DISPERSION COMPOSITIONS AND USES THEREOF

(57) Abstract: Solid Dispersion Compositions and Uses Thereof The present specification discloses pharmaceutical composition disclosed herein comprises one or more therapeutic compounds, one or more glycerolipids, and one or more digestion enhancers. The disclosed one or more therapeutic compounds comprise a solid particle component, a solubilized component, or both. The disclosed glycerolipids comprise one or more hard fats and one or more liquid fats. The disclosed digestion enhancers comprise one or more bile acids, one or more phospholipids, one or more free C14-24 fatty acids, one or more free C14-24 fatty acid surfactants, or any combination thereof. The present specification also discloses methods and procedures to formulate the disclosed one or more therapeutic compounds into the disclosed pharmaceutical compositions. The present specification further discloses methods and uses of the disclosed pharmaceutical compositions in the treatment of an inflammation and/or neuroinflammation.



WO 2025/093572 A1